SGLT2 inhibitors lower stroke, mortality risks in AF patients with T2DM
Treatment with SGLT2 inhibitors appears to reduce the risks of stroke, dementia, long-standing persistent atrial fibrillation (AF), heart failure, and mortality in patients with both AF and type 2 diabetes mellitus (T2DM), suggests a recent study.